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ABSTRACT
The T cell hypothesis of asthma, particularly chronic 
asthma, is based around the concept that the disease 
is 'driven' and maintained by the persistence of a 
specialized subset of chronically activated T-memory 
cells, sensitized against an array of allergenic, 
occupational or viral antigens that 'home' to the lung 
after appropriate antigen exposure or viral infection. 
Allergens induce a CD4 T-helper (Th) cell response, 
whereas viruses recognize CD8+ cytotoxic (Tc) cells. In 
the asthmatic airways there appears to be both CD4+ 
and CD8+ cells with a type 2 cytokine phenotype (i.e. 
Th2- and Tc2-types). These cells produce interleukin 
(IL)-5, IL-3 and granulocyte/macrophage-colony 
stimulating factor, which recruit, mobilize and activate 
eosinophils for subsequent mucosal tissue damage,
and IL-4, an essential co-factor for local or 
generalized immunoglobulin (Ig) E production. This in 
turn leads to 'eosinophilic desquamative bronchitis' 
with epithelial shedding, mucus hypersecretion and 
bronchial smooth muscle contraction. Thus, although 
the eosinophil is believed to produce airway damage, 
function appears to be under T cell control. Support for 
this hypothesis includes the observations that activated 
T cells and their products can be identified in biopsies 
from the major variants of the disease (atopic, non-
atopic ('intrinsic') and occupational asthma), the co-
localization of mRNA for type 2 cytokines to CD4+ and 
CD8+ cells in atopic and non-atopic asthma, the 
presence of chronically activated cytokine-producing T 
cells in corticosteroid-resistant asthma, the association
of disease severity with type 2 cytokines, particularly IL-
5, and the efficacy of cyclosporine A in chronic steroid-
dependent disease. Inhibitors and/or antagonists 
directed against more precise T cell-associated 
molecular targets hold promise for the future 
treatment of chronic asthma.
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INTRODUCTION
Up to the mid-1980s there was a fairly general consensus 
that the mast cell was central in the pathophysiology of 
asthma. At the 3rd International Symposium on Asthma1 it 
was suggested that 'perhaps asthma is no more than 
physical allergy of the mast cells of the lung', the analogy 
being made with urticaria, where it was established that 
allergic and non-allergic triggers could release histamine 
(and presumably other mediators) from mast cells, which 
in turn produced the urticarial lesion. Thus, asthma, 
which was characterized clinically as intermittent airway 
narrowing, was believed to result, in atopic asthma, from
intermittent type I (immediate-type hypersensitivity) 
reactions by immunoglobulin (Ig) E-dependent mast cell 
mediator release or by mast cell degranulation due to 
physical or other stimuli in non-atopic ('intrinsic') asthma. 
The hypothesis explained both atopic and non-atopic 
asthma as well as the mode of action of drugs, such as 
sodium cromoglycate, considered at that time to work 
principally through the stabilization of mast cells. Set 
ag inst the 'leaky mast cell' theory was the observation 
that corticosteroids, a mainstay in asthma treatment since 
the 1950s, had no effect on histamine release from 
dispersed mast cells from human lung tissue. 
Furthermore, agents such as antihistamines, which 
antagonize the effects of mast cell mediators, were shown 
to have little effect in asthma. In addition, the mast cell
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hypothesis did not explain why only a proportion of 
atopic subjects are asthmatic as mast cell degranulation 
may be expected to produce similar symptoms in any 
sensitized individual. Most important was the realization 
that even between acute attacks the asthmatic airways 
were hyperresponsive to non-specific stimuli such as 
histamine, even when the patient was asymptomatic, 
and, thus, the concept of asthma as a chronic 
inflammatory disease emerged. This was given greater 
credence by the application of fibre-optic bronchoscopy 
and the ability to study the inflammatory infiltrate in the 
airway mucosa of asthmatics. This advance in the early 
1980s soon established that an eosinophilic and 
mononuclear cell infiltrate was a feature of asthmatic 
airways, even in the absence of symptoms. By 1987, 
asthma definitions included eosinophilic airway 
hyperresponsiveness, airway inflammation and 
desquamative bronchial eosinophilia as characteristics of 
the disease. 
 There were several reasons for turning to the T cell for 
clues as to what 'drives' the asthma process, not the least 
being the exquisite sensitivity of T cells to the anti-
proliferative action of corticosteroids (drugs that remain 
the mainstay of treatment of the disease). Also, at this
time, there had been a considerable increase in the 
understanding of the allergic response in terms of the 
essential role of T cells in both antibody mediated and 
cell-mediated hypersensitivity reactions. 
THE T CELL HYPOTHESIS OF ASTHMA 
The T cell hypothesis of asthma, particularly chronic 
asthma, is based around the concept that the disease is 
'driven' and is maintained by persistence of a specialized 
subset of chronically activated T memory cells, sensitized 
against an array of allergenic, occupational and viral 
antigens that 'home' to the lung after appropriate 
antigen exposure or viral infection (Fig. 1). Allergens 
induce a CD4+ T helper (Th) cell response, whereas 
CD8+ cytotoxic (Tc) cells recognize virally infected cells. In 
the asthmatic airways CD4+ and CD8+ cells have a type 
2 (Th2/Tc2) cytokine profile, producing interleukin (IL)-5, 
IL-3 and granulocyte/macrophage-colony stimulating 
factor (GM-CSF), which mobilize and activate 
eosinophils for subsequent mucosal tissue injury, as well 
as IL-4, which is an essential co-factor for local or 
g neral IgE production. These events lead to an 
'eosinophilic desquamative bronchitis' with epithelial
Fig. 1 The T cell hypothesis of chronic asthma.
ROLE OF T CELLS IN ASTHMA 75
shedding, mucous hypersecretion and bronchial smooth 
muscle contraction. Thus, although the eosinophil is 
largely responsible for asthma symptoms, its function is 
under T cell control. 
 This hypothesis has been tested in several ways and 
including the identification of activated T cells and T cell 
products' in baseline asthma compared with relevant 
controls,2 after provoked asthma,3 in relation to clinical 
features,4 after other successful treatment of asthma,5 in 
corticosteroid-resistant asthma6 and in atopic and non-
atopic (intrinsic) asthma. Most of these studies have 
addressed the interrelationship between activated T cells 
(and their products), the eosinophil and disease severity. 
  Of particular interest are recent genetic studies of 
atopy and asthma that have linked inheritance to 
candidate genes in either the 5q31.1 locus, which 
encodes many type 2 cytokines,2 or in T cell receptor 
genes.3
ACTIVATED T CELLS
Strong support for the hypothesis initially came from the 
observation that, compared with controls, the numbers of 
activated (CD4+/CD25+) T helper cells in peripheral 
blood were markedly elevated in patients admitted to 
hospital with acute severe asthma ('status asthmaticus').4 
There was also a direct correlation between the numbers 
of activated peripheral blood T cells and airway 
narrowing as measured by the peak expiratory flow rate 
(PEFR). Jeffery et al.5 identified a striking increase in the 
number of 'irregularly shaped' lymphocytes in the lamina 
propria and submucosa of endobronchial mucosal 
biopsies from symptomatic asthmatics. Immuno-
histochemical studies suggested that these irregularly 
shaped cells were probably activated T cells.6 There was 
also the expected increase in the numbers of eosinophils 
in asthma compared with controls. By double 
immunofluorescence, the majority (>85%) of CD25+ 
cells were CD3+T cells,7 while by flow cytometric analysis 
of bronchoalveolar lavage (BAL) cells Robinson et al.8 
found a correlation between CD4+/CD25+ lymphocytes 
and eosinophils in BAL with the majority of CD4+ cells 
being of the memory (CD45RO+) phenotype. 
  Some studies have suggested increases in CD8+ cells 
in biopsies from occupational asthma9,10 and in a mouse 
model it was shown that virus-specific CD8+ cells can 
switch to IL-5 production and induce airway 
eosinophilia.11 One interpretation of this finding is that 
some variants of asthma are a form of autoallergic
disease in which viruses or chemical haptens modify 
intrinsic antigens that, in turn, are targeted by CD8+ 
cyt toxic cells. Determining the frequency of usage of the 
T cell antigen receptor (TcR) variable (TcR V) gene families 
nd functional analysis among T cells isolated from 
asthmatic airways may also provide indirect evidence for 
T cell responsiveness to as yet unidentified antigens.
CYTOKINES
Interleukin-5, of which the T cell is an important source, 
promotes terminal differentiation of the committed 
eosinophil precursor as well as enhancing the effector 
capacity of the mature eosinophil.12 lnterleukin-5 also 
prolongs the survival of eosinophils in vitro and anti-IL-5 
inhibits allergen-induced bronchial hyperresponsiveness 
and eosinophilia in a primate model of asthma.13 In order 
to strengthen the hypothesis that products of activated T 
cells regulate local eosinophilia in asthma, Hamid et al.14 
identified elevated numbers of IL-5 mRNA+ cells in 
endobronchial mucosal biopsies from asthmatics 
c pared with controls. Within the subjects who 
demonstrated detectable IL-5 mRNA there was a 
correlation between IL-5 mRNA expression and the 
number of CD25+ and EG2+ cells and total eosinophil 
count .1 Again, this study supported the concept that in 
the b onchial mucosa of asthmatics T cell-derived 
cytokines regulate eosinophil accumulation and function. 
  In  study examining the wider cytokine profile in 
atopic asthma, Robinson et al.15 showed that, compared 
with cells from non-atopic control subjects, there were 
increased numbers of BAL cells encoding mRNA+ for IL-
3, IL-4, IL-5 and GM-CSF, a pattern compatible with 
predominant activation of the Th2-type T cell population. 
Messenger RNA for IL-4 and IL-5 was localized to T cells 
within the BAL cell population. These findings were 
confirmed using CD4+- and CD8+-enriched peripheral 
blood T cells isolated from patients with severe asthma.'b 
These individuals, but not controls, showed spontaneous 
expression of mRNA for Th2-type cytokines localized to 
CD4, but not CD8+, cells. This was accompanied by 
spontaneous elaboration of the eosinophil-active 
cytokines IL-3, IL-5 and GM-CSF 
  Conversely, prednisolone treatment in asthmatics was 
ass ciated with a reduction in BAL cells expressing mRNA 
for IL-4 and IL-5.17,18 This was accompanied by a 
decrease in BAL eosinophils and clinical improvement, as 
shown by an increase in the methacholine PC20 (provo-
cation concentration causing a 20% fall in FEV1).
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Interestingly, there was an increase in the number of cells
expressing mRNA for interferon(IFN)-γ, indicating that
prednisolone treatment favours enhancement of a 
cytokine that down-regulates IgE production. 
 Using the technique of in situ hybridization, it was 
shown that, in a group of atopic asthmatics with a range 
of disease severity, there were significant associations 
between the numbers of cells expressing mRNA for IL-4, 
IL-5 and GM-CSF and airflow restriction, bronchial 
hyperresponsiveness and an asthma symptom score.19 
These results have recently been confirmed (in the case of 
lL-5) using a more precise semiquantitative reverse 
transcription-polymerase chain reaction (RT-PCR) 
technique.20 Furthermore, Virchow et al.,21 using 
segmental allergen challenge, found a correlation 
between IL-5 concentrations, eosinophil numbers and 
activated T cells, again supporting the hypothesis that T 
cell-derived IL-5 is involved in tissue eosinophilia in 
allergic asthma. 
 Although several authors have now confirmed that 
asthma is characterized by elevated expression, at either 
the mRNA or protein levels, of several cytokines, 
including IL-4 and IL-5, there has been some debate as to 
the principal cellular source of these cytokines. Our 
experience using double in situ hybridization/ 
immunohistochemistry is that T cells are the major source 
of mRNA encoding IL-4 and IL-5 in asthmatics compared
with controls.22 Eosinophils and mast cells also contribute 
to the overall cytokine profile, although the numbers of 
mRNA+ cells were approximately one-fifth compared to 
that of the CD3+ T cell. Furthermore, we have been able 
to establish, using a combination of semiquantitative 
PCR, in situ hybridization and immunohistochemistry, that 
the amount and the cellular origin of IL-4 and IL-5 
expression was similar in bronchial biopsies taken from 
atopic and non-atopic asthmatics with, in general, IL-5 
being significantly higher in asthmatics compared with 
atopic non-asthmatic normal controls, whereas IL-4 was 
elevated in asthma and atopic non-asthmatics compared 
with normal non-atopic controls.20 The detection of 
elevated IL-4 mRNA-bearing cells in atopic non-
asthmatic bronchial mucosal biopsies by the sensitive 
technique of RT-PCR, raises the possibility that, in 
general, IL-5 is related more closely to clinical expression 
of asthma, whereas IL-4 is related to over-production of 
IgE. In both atopic and non-atopic asthmatics, mRNA for 
IL-4 and IL-5 colocalized predominantly to CD4+ but also 
to CD8+ T cells,23 findings in agreement with those of Till
et a .,24 who found that CD8+ as well as CD4+ T cell lines 
from BAL from asthmatics elaborated the IL-5 protein. 
These findings are compatible with the concept of T 
cytotoxic type 2 (Tc2) lymphocytes. Our finding of 
elev ted IL-4 expression at both the mRNA and protein 
levels in intrinsic asthma was in contrast to the findings of 
W lker et al.25 who measured protein product in 
concentrated BAL fluid. These authors detected increased 
concentrations of IL-2 and IL-5 (but not IL-4) in BAL fluid 
from non-atopic asthmatics compared with control 
subjects, whereas IL-4 and IL-5 were increased in atopic 
asthmatics.25 There is, at present, no satisfactory 
explanation for these apparent discrepancies. The role of 
Th2-type cells in intrinsic asthma, as well as that of local 
IgE-dependent mechanisms, as suggested by Humbert 
et l.,26 is unlikely to be resolved until the putative 
antigen(s) have been identified.
 In contrast to mRNA, the expression of the IL-4 and IL-
5 protein product in bronchial biopsies from atopic and 
non-atopic asthmatics appeared to be associated more 
wi h eosinophils and mast cells than T cells.23,2' There are 
difficulties in demonstrating intracytoplasmic staining of 
cytokines in non-granular cells, such as T cells, 
presumably because of the limitations of sensitivity of 
current immunostaining methods. However, the 
eosinophil appears to concentrate several cytokines in its 
cell granule with granule-associated cytokines being 
readily detectable by immunocytochemistry.28,29 Despite 
these limitations of the immunocytochemical detection of 
cytokines, it seems likely that T cells are an important 
source of IL-4 and IL-5 in asthma, although the relative 
contribution of the different cell types to the overall 
cytokine profile remains uncertain. 
  Recent examination of IL-12 mRNA expression in 
b nchial biopsies from asthmatic subjects and controls 
suggests that there may be a defective IL-12 response in 
asthma: this may also favour a Th2 environment.30 This 
would be in keeping with the observation of increased IL-
12 mRNA-encoding cells in cutaneous late responses 
after immunotherapy, where it was suggested that 
i duction of an IL-12 response may be protective.31
T CELL HOMING RECEPTORS
It is known from work with mice that the traffic of 
lymphocytes to lymph nodes and Peyer's patches is 
controlled, in part, by the interaction of lymphocyte 
adhesion molecules called 'homing receptors'. These
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bind to tissue-selective endothelial ligands known as
vascular addressins. For example, in the gut, α4β7 integrin
and L-selectin, expressed on T cells, are involved in 
complex interactions with the mucosal addressins 
MadCAM-1, VCAM-1 ,GlyCam-1 and CD34 expressed
on vascular endothelium.32α4β7ligates predominantly
with VCAM-1 and MadCAM-1 with L-selectin binding to 
MadCAM-1, GIyCAM-1 and CD34. Similarly, the 
cutaneous lymphocyte antigen (CLA) is believed to 
represent a skin-homing receptor for T cells through 
interaction with E-selectin on endothelial cells. 
Santamaria et a1.33,34 observed that CLAP, CD45R0+ 
(memory/effector), but not CLA-CD45R0+, T cells from 
the blood of patients with allergen contact dermatitis or 
atopic eczema specifically proliferated in response to 
specific antigen. In contrast, peripheral blood CLA-, 
CD45RO+ cells from asthmatics proliferated in response 
to allergen, suggesting that there may be an as yet 
unidentified bronchial homing receptor in defined
memory T cell subsets.34
GLUCOCORTICOID RESISTANCE IN ASTHMA
Glucocorticosteroids are remarkably effective in the 
majority of asthmatics in controlling symptoms. In vitro, 
very low doses inhibit T cell proliferative responses to 
mitogens; concentrations of methylprednisolone as low 
as 10-10 mol/L being effective in inhibiting human T cell 
expansion. A small proportion of asthmatic subjects do 
not show clinical improvement with glucocorticoid 
treatment (reviewed by Kay et al.35). Formal definitions 
vary, but most would encompass failure to show a 10% or 
more increase in forced expiratory volume in 1 s (FEV1) 
after 2 weeks treatment with 40mg/day prednisolone or 
equivalent in subjects with asthma symptoms and 
demonstrated reversibility of airflow obstruction of at least
15% to inhaled β-adrenoceptor ogonists.It is not clear
whether this is a distinct group or a continuum of clinical 
responsiveness, but glucocorticoid resistance is also seen 
in other inflammatory diseases. Peripheral blood mono-
nuclear cells from patients with corticosteroid-resistant 
asthma proliferated to phytohaemagglutinin in the 
presence of relatively high doses of methylprednisolone 
and a clear relationship was shown between clinical 
responsiveness to steroids and the in vitro effect of 
steroids on mitogen-driven colony counts. This adds 
support to the T cell hypothesis of asthma, as both T cell 
proliferation and cytokine production are exquisitely
sen itive to steroid inhibition and the in vitro 
responsiveness of T lymphocyte proliferation and cytokine 
production was closely correlated with clinical response 
to glucocorticoids. 
 The mechanisms of steroid resistance are unclear. It 
has been suggested that steroid-resistance may arise 
from the cytokine environment of the T cell. Sher et al.36 
found that the majority of patients with steroid-resistant 
(SR) asthma had a reversible defect in glucocorticosteroid 
receptor (GR) binding affinity, which could be sustained in 
vitro by the addition of the combination of IL-2 and IL-4 
but not the individual cytokines. Furthermore, in vitro 
incubation of normal T cells with the combination of IL-2 
nd IL-4, in the absence of IFN-y reduced their GR 
binding affinity to the levels seen in SR asthma.36 On this 
basis Sher et al.36 suggested two types of 
glucocorticosteroid resistance: a reduced affinity of GR 
binding confined to T lymphocytes, which reverted to 
normal after 48h in culture, and a much less common 
reduction in GR density (in only two of 17 SR patients), 
which did not normalize with prolonged incubation. This 
supported the concept that there may be different types of 
steroid resistance in asthma. These in vitro data 
suggested that the pattern of cytokine gene expression 
may play a role in determining steroid resistance. For this 
r ason Leung et al.37 used the technique of in situ 
hybridization to examine whether airway cells from SR 
asthmatics compared with steroid-sensitive (SS) 
asthmatics expressed different patterns of mRNA for 
cytokines, particularly after treatment with oral steroids. 
They confirmed that SS asthmatics responded well to 
glucocorticoids and this was accompanied by a decrease 
in the numbers of cells expressing mRNA for IL-4 and IL-5
and an increase in IFN-γ transcripts. In contrast, after
prednisolone therapy, SR asthmatics had no significant 
changes in either the number of BAL cells expressing 
mRNA for IL-4 or IL-5. Furthermore instead of a decrease
there was an increase in the numbers of IFN-γ mRNA+
cells. These findings suggest that SR asthma is associated 
with dysregulation of expression of the genes encoding 
Th2/Th1 cytokines in airway cells and are compatible 
with the concept that a combination of IL-2 and IL-4 
induce GR binding affinity and T cell responsiveness to 
glucocorticoids. 
 Studies by Adcock et al.38 have suggested 
dy regulation of transcription factors in glucocorticoid-
resistant asthma, with increased expression of the pro-
inflammatory activator protein (AP)-1 interfering with
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steroid actions by cytoplasmic binding to the GR. Small 
alterations in glucocorticoid pharmacokinetics and 
igand binding affinity are also seen in these subjects, but 
are probably insufficient to account for the clinical 
features.
CYCLOSPORINE A
It is generally accepted that the primary mode of action of 
cyclosporine A (CsA) is through inhibition of T cell 
activation secondary to blocking of early calcium-
dependent transcription of mRNA encoding several 
cytokines. In a group of severe steroid-dependent 
asthmatics, treatment over a 12 week period with CsA at 
low dosage (5mg/kg per day) was associated with 
improvement in lung function and a reduction in the 
numbers of disease exacerbations requiring an increase
in corticosteroid dosage.39 Two further studies40,41 have 
shown a corticosteroid-sparing effect of CsA in steroid-
dependent asthmatics. In both studies lung function 
concurrently improved despite the reduction in 
corticosteroid dose, although in one study this 
improvement was small. 
 It is generally accepted that the late-phase asthmatic 
response provoked by inhaled allergen represents a 
model of asthmatic airway inflammation because the 
pathogenesis of the disease, at least in part, is believed to 
involve the mobilization and local influx of eosinophils 
subsequent to the release of IL-5, IL-3 and GM-CSF from 
activated T cells. In contrast, mediators released from 
IgE-sensitized mast cells have been implicated in the 
pathogenesis of the allergen-induced early phase 
asthmatic response (EAR). Because CsA inhibits both 
cytokin  mRNA transcription by T cells and mast cell
Fig. 2 Possible future therapeutic strategies in asthma, based on the T cell hypothesis. Approaches include blocking of co-
stimulation with agents such as CTLA-4 Ig, which may inhibit T-cell activation, or co-administration of IL-12 (possibly together with 
allergen in immunotherapy), which may enhance switching from a Th2 to a Thl predominant T cell response. Direct blocking 
antibodies to IL-4 and IL-5 may have therapeutic efficacy. Other possible strategies include T-cell directed antibody therapy with 
monoclonal antibodies directed against CD4, or immunosuppressants such as FK506, rapamycin and mycophenalate mofetil.
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degranulation in vitro, it may be expected to inhibit both 
the EAR and LAR as well as the associated elevation in 
blood eosinophils. Sihra et aI.42 have recently 
demonstrated, in a double-blind, placebo-controlled, 
randomized crossover trial, that compared with placebo 
treatment, CsA reduced the magnitude of the LAR but not 
the EAR following allergen challenge. This provides 
strong indirect evidence that CsA is effective in this model 
of asthmatic allergic inflammation through its effects on 
the T cell as opposed to mast cells and basophils.
FURTHER DEVELOPMENTS
There is now persuasive evidence to support the 
hypothesis that activation of Th2 cells and/or Tc2 cells is 
pivotal to the asthma process. The hypothesis is 
supported by numerous lines of evidence, particularly 
studies of bronchoalveolar lavage and bronchial biopsies 
from asthmatic subjects, in treatment studies and in 
experimental animal models. 
 The T cell hypothesis of chronic asthma has led to the 
possibility of a number of novel therapeutic approaches 
(Fig. 2 and reviewed by Kay et al.35). These include: (i) 
strategies to inhibit co-stimulatory pathways (e.g. CTLA4 
Ig and anti-B7-2); (ii) agents that modulate the Th2 
response (e. g. IL-12); (iii) humanized antibodies against 
CD4 (shown to have efficacy in rheumatoid arthritis); (iv) 
anti-cytokine antibodies, particularly against IL-4 and IL-
5 and cytokine receptor antagonists (e. g. the IL-1 
receptor antagonist shown to modulate human 
cutaneous late responses to allergen); (v) a range of 
immunosuppressive drugs, including FK506, rapamycin 
and mycophenalate mofetil, all of which are active in 
inhibiting mitogen-driven T cells from corticosteroid-
resistant asthmatics in vitro; and (vi) anti-eosinophil 
strategies (e.g. antibodies or other agents directed 
against CCR3 (the receptor for the eosinophil-active CC 
chemokines, eotaxin, RANTES, MCP-3 and MCP-4)).
 A number of important questions still remain 
unanswered, including (i) what initiates the Th2/Tc2 
response in asthma and allergy; (ii) how does asthma 
differ from atopy alone at the immunopathological level: 
not all atopics have asthma; (iii) what proportion of 
activated T cells in the bronchial mucosa are allergen (or 
antigen)-specific; (iv) what is the role of CD8 T cells in 
asthma; and (v) what is the role of other cell types in 
modifying the T cell response and in perpetuating airway 
inflammation in asthma? It is anticipated that with
advances in molecular pathological techniques and 
more precise and selective therapy, many of these 
questions can be answered.
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